Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...

HSBC on Monday double downgraded Eli Lilly and Co. (LLY) stock to ‘Reduce’ from ‘Buy’ and also lowered its price target to ...

Neoadjuvant PD-1 blockade in dMMR tumors "could potentially eradicate the need for chemotherapy, radiation, and surgery in ...

IBM is making a major bet on America's tech future. The company announced plans on Monday to invest $150 billion across the ...

Six years into espnW Summit NYC, brands increasingly want in on the gathering of institutional women's sports knowledge. In ...

The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research ...

HSBC analyst warns of a downside in Eli Lilly stock to $700. Rajesh Kumar cited 'valuation' as his number 1 concern.

Eli Lilly and Company LLY will report its first-quarter earnings on May 1, before market open. The Zacks Consensus Estimate for sales and earnings is pegged at $12.62 billion and $3.52 per share, ...

With its 2-star rating, we believe Lilly stock is overvalued compared with our long-term fair value estimate of $650 per ...

Top US firms are boosting executive security spending after the killing of UnitedHealth’s Brian Thompson, with costs expected ...

President Donald Trump is under pressure to decide how widely available anti-obesity drugs should be and whether Medicare should cover them.

We recently published a list of Billionaire Ken Fisher’s 10 Healthcare Stock Picks with Massive Upside Potential.